Selexis SA and Turgut Pharmaceuticals (Turgut Ilaclari A.S.) announced today that they have signed two commercial license agreements (CLAs) through which Turgut will leverage Selexis’ SUREtechnology Platform? and ...
Selexis SA and Hoba Therapeutics announced today that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of peripheral neuropathic pain.